What the label states, the lot delivers — net peptide mass, not gross powder weight, purity reported as measured rather than rounded up, and a Certificate of Analysis for every lot.
Net peptide mass, not powder weight; purity as measured, not rounded up; a COA per lot.
Net peptide + purity not rounded up. COA per lot.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
Body Protection Compound 15-mer
Vialdyne primary owner
This is the primary page for pharmacy buyers evaluating BPC-157 as a documented active rather than as a generic repair-peptide catalog entry. It should answer sequence identity, LC-MS/MS add-on, PCAC context, blend options, and what evidence a pharmacy QA team should request at supplier onboarding.
Overview
BPC-157 (Body Protection Compound 15-mer) is a 15-amino-acid sequence, GEPPPGKPADDAGLV, derived from a protective fragment originally isolated from human gastric juice. The unusually high proline content of the N-terminal half (four prolines in the first eight residues) kinks the backbone in a way that resists protease access, giving the molecule notable stability in gastric and serum environments and underwriting its use across tendon-ligament, GI mucosal, vascular endothelial, and bone-repair research models. For 503A patient-specific compounders watching the regulatory pipeline: BPC-157 is currently scheduled for FDA PCAC review at the July 2026 meeting against the 503A bulks-list criteria. The procurement and regulatory framing is broken out in two companion articles: our overview of the [503A vs 503B compounding pathways](/insights/503a-vs-503b-compounding-pharmacy-peptides), plus the dedicated [BPC-157 procurement playbook for pharmacies](/insights/bpc-157-sourcing-guide-compounding-pharmacies). Vialdyne releases BPC-157 acetate as a lyophilised powder against a ≥99.0% main-peak HPLC specification. The 15-residue sequence is reliably accessible by SPPS, but the closely-eluting truncation by-products require disciplined purification, so every batch ships with peak-integration RP-HPLC plus ESI-MS confirming the molecular weight inside 0.5 Da of the 1419.55 g/mol theoretical. LC-MS/MS sequence verification with a full b- and y-ion ladder is the recommended qualification add-on for any first-time pharmacy onboarding, ESI-MS alone confirms mass identity, but tandem MS directly proves the synthesised sequence matches the labelled sequence. BPC-157 also feeds the co-lyophilised Wolverine Blend (with TB-500) and the GLOW Blend (with TB-500 and GHK-Cu). For a direct mechanism-and-analytical comparison with TB-500, see the [BPC-157 vs TB-500 article](/insights/bpc-157-vs-tb-500-side-by-side).
Applications & buyer fit
Repair peptides, BPC-157, TB-500, and related sequences, typically ship to research labs studying tissue-repair, gastrointestinal, or tendon-ligament models, and to compounding pharmacies that have validated the active material into their workflow. The synthesis itself is reliable, but analytical confirmation is where suppliers differ, buyers qualifying a new source should request sequence verification by tandem MS on the first batch and compare against the labelled sequence directly.
Sourced for
Buyer fit
Documentation that ships
Procurement note: Buyers qualifying a new source typically request tandem-MS sequence verification on the first lot, compared against the labelled sequence.
Primary buyer fit: 503A / 503B compounding pharmacies and academic and contract research laboratories.
Specifications
Certificate of Analysis
Published released-batch COAs for BPC-157, every lot HPLC-verified. These are previews — request the full high-resolution certificate for any lot.
VerifiedRequest full COA →BPC-157
VD260428-BC10035 · 98.94%
VerifiedRequest full COA →BPC-157
VD260428-BC033 · 99.62%
VerifiedRequest full COA →BPC-157
VD260428-BC5034 · 99.25%
Regulatory note
Inclusion of BPC-157 on the 503A bulks list is presently before the FDA's PCAC (July 2026). We provide it for research together with commercial use, subject to the buyer's local regulations.
Selected literature
Frequently asked questions
Sequence is GEPPPGKPADDAGLV across 15 residues. The first eight residues alone contain four prolines (PPPGKP segment), and the resulting backbone geometry leaves few cleavage-accessible peptide bonds. The molecule therefore tolerates gastric and serum protease environments far better than typical short peptides, which is the same property that underwrites the published research on oral-route protocols. By contrast, TB-500 is restricted to injectable routes because its longer, more flexible backbone does not survive gastric exposure.
There is no approved finished drug containing BPC-157 in any major jurisdiction at the time of writing. The active is currently scheduled for FDA Pharmacy Compounding Advisory Committee (PCAC) review at the July 2026 meeting, with the proposed indication of ulcerative colitis, under consideration for inclusion on the 503A bulks list. If PCAC's recommendation is accepted by the FDA, 503A pharmacies would gain a clear path to patient-specific compounding using BPC-157. Until that happens, sales are restricted to API use in jurisdictions where local rules permit and to compounding under the receiving pharmacy's own regulatory analysis.
Acetate is the default salt released against the catalogue spec and is the form most pharmacies want, the chromatographic behaviour and reconstitution kinetics are well characterised. Free-base BPC-157 is occasionally requested where a downstream formulator needs to control the final counter-ion themselves. Per-mass biological activity is equivalent across the two; the practical differences are in RP-HPLC retention time (acetate elutes slightly earlier under typical gradient conditions) and in handling pH. Flag salt-form preference at the quote stage so the lot is reserved correctly.
Yes, this is the Wolverine Blend SKU, one of the most-requested co-lyophilised presentations in the catalogue. Co-lyophilisation is operationally preferred over having the receiving pharmacy reconstitute and combine two separate vials, the released-batch COA certifies the actual ratio in the cake rather than the nominal ratio. Standard fill is 5 + 5 mg in a 10 mg total vial; non-standard ratios (10+5, 10+10, 5+10) can be scoped under a project-specific change-control. Adding GHK-Cu to the blend produces the GLOW Blend SKU, intended for compounding workflows that combine tissue-repair and integumentary endpoints in a single dispense.
